| Mr James Robert Martin, MPAS | |
|
1490 E Foremaster Dr, Ste 150, St George, UT 84790-4488 | |
| (435) 628-9393 | |
| (435) 628-9382 |
| Full Name | Mr James Robert Martin |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Location | 1490 E Foremaster Dr, St George, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427157148 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080A0000X | Pediatrics - Adolescent Medicine | 288527-1206 (Utah) | Secondary |
| 363A00000X | Physician Assistant | 288527-1206 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr James Robert Martin, MPAS 1055 N 500 W, Provo, UT 84604-3305 Ph: (435) 628-9393 | Mr James Robert Martin, MPAS 1490 E Foremaster Dr, Ste 150, St George, UT 84790-4488 Ph: (435) 628-9393 |
News Archive
A new study by Craig Thiessen, M.D., Director of Radiology for West Houston Radiology L.L.P. and North Cypress Medical Center in Houston, presented this week at the National Consortium of Breast Centers Annual Meeting, found the improved photon sensitivity of new detector technologies such as PSPMTs and CZT should be capable of reducing the radiation dose patient receive from BSGI/MBI studies by 75%.
Areas of the brain in blind people can learn to process visual input through the use of sound, even after years or perhaps even lifelong blindness, according to new research reported in the November issue of the Cell Press journal Neuron. The findings challenge the common belief that if the visual cortex of the brain is deprived of information in early life, it may never develop functional specialization.
IntegraMed America, Inc., a leader in developing, marketing and managing specialty healthcare facilities in the fertility and vein care markets, announced today that it has entered into a definitive agreement to be acquired by affiliates formed by Sagard Capital Partners, L.P., an investment fund and IntegraMed shareholder, for $14.05 per share in cash, or a total equity purchase price of $169.5 million.
Telesta Therapeutics Inc. announced today that it has submitted electronically, through its U.S. agent, a Biologics License Application (BLA) to the United States Food and Drug Administration for MCNA. MCNA is Telesta's novel biologic immunotherapeutic for the treatment of high-risk non-muscle invasive bladder cancer patients who have failed first-line BCG therapy.
A retrospective study led by Northwestern Medicine investigators found that the chimeric antigen receptor (CAR) T-cell immunotherapy drug tisagenlecleucel demonstrated safety and efficacy in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia (B-cell ALL), even when the drug doesn't meet the FDA's strict manufacturing standards.
› Verified 4 days ago